PYXIS ONCOLOGY INC (PYXS) Stock Price, Quote, News and Overview
NASDAQ:PYXS - Nasdaq - US7473241013 - Common Stock - Currency: USD
PYXS Quote, Performance and Key Statistics
1.07
-0.12 (-10.08%)
The current stock price of PYXS is 1.07 USD. In the past month the price increased by 16.94%. In the past year, price decreased by -74.22%.
PYXS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.28 | 313.89B | ||
| AMGN | AMGEN INC | 12.63 | 141.01B | ||
| GILD | GILEAD SCIENCES INC | 12.71 | 122.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 108.27B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.89 | 61.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.80B | ||
| ARGX | ARGENX SE - ADR | 90.68 | 32.50B | ||
| ONC | BEIGENE LTD-ADR | 5.46 | 23.71B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.14B | ||
| NTRA | NATERA INC | N/A | 20.57B | ||
| BIIB | BIOGEN INC | 7.61 | 17.64B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.90B |
Related stock screener links
About PYXS
Company Profile
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Company Info
PYXIS ONCOLOGY INC
321 Harrison Avenue
Boston MASSACHUSETTS US
Employees: 55
Phone: 16172219059
PYXIS ONCOLOGY INC / PYXS FAQ
What is the stock price of PYXIS ONCOLOGY INC today?
The current stock price of PYXS is 1.07 USD. The price decreased by -10.08% in the last trading session.
What is the ticker symbol for PYXIS ONCOLOGY INC stock?
The exchange symbol of PYXIS ONCOLOGY INC is PYXS and it is listed on the Nasdaq exchange.
On which exchange is PYXS stock listed?
PYXS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PYXIS ONCOLOGY INC stock?
13 analysts have analysed PYXS and the average price target is 7.34 USD. This implies a price increase of 586.36% is expected in the next year compared to the current price of 1.07. Check the PYXIS ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PYXIS ONCOLOGY INC worth?
PYXIS ONCOLOGY INC (PYXS) has a market capitalization of 66.29M USD. This makes PYXS a Micro Cap stock.
How many employees does PYXIS ONCOLOGY INC have?
PYXIS ONCOLOGY INC (PYXS) currently has 55 employees.
What are the support and resistance levels for PYXIS ONCOLOGY INC (PYXS) stock?
PYXIS ONCOLOGY INC (PYXS) has a support level at 1.06 and a resistance level at 1.19. Check the full technical report for a detailed analysis of PYXS support and resistance levels.
Is PYXIS ONCOLOGY INC (PYXS) expected to grow?
The Revenue of PYXIS ONCOLOGY INC (PYXS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the PYXS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PYXIS ONCOLOGY INC (PYXS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PYXS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PYXS, evaluating the profitability, health, valuation and growth aspects
- PYXIS ONCOLOGY INC (PYXS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PYXIS ONCOLOGY INC (PYXS) Sales and EPS estimates to see what analysts future expectations are.
- PYXIS ONCOLOGY INC (PYXS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PYXIS ONCOLOGY INC (PYXS) Insider and Institutional Ownership to learn about the owners and their transactions.
- PYXIS ONCOLOGY INC (PYXS) Stock Chart to make your own analysis
- PYXIS ONCOLOGY INC (PYXS) Latest news and press-releases to stay up to date.
Does PYXIS ONCOLOGY INC (PYXS) stock pay dividends?
PYXS does not pay a dividend.
When does PYXIS ONCOLOGY INC (PYXS) report earnings?
PYXIS ONCOLOGY INC (PYXS) will report earnings on 2025-08-12, before the market open.
What is the Price/Earnings (PE) ratio of PYXIS ONCOLOGY INC (PYXS)?
PYXIS ONCOLOGY INC (PYXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.95).
What is the Short Interest ratio of PYXIS ONCOLOGY INC (PYXS) stock?
The outstanding short interest for PYXIS ONCOLOGY INC (PYXS) is 15.34% of its float. Check the ownership tab for more information on the PYXS short interest.
PYXS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PYXS. When comparing the yearly performance of all stocks, PYXS is a bad performer in the overall market: 92.86% of all stocks are doing better.
PYXS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PYXS. PYXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PYXS Financial Highlights
Over the last trailing twelve months PYXS reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS increased by 48.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.2% | ||
| ROE | -64.04% | ||
| Debt/Equity | 0 |
PYXS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to PYXS. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -20.25% and a revenue growth -100% for PYXS